A Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenously Administered BMS-986446 in Healthy Participants Including Healthy Participants of Japanese Ethnicity
Latest Information Update: 19 Mar 2024
At a glance
- Drugs BMS 986446 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 14 Mar 2024 Status changed from active, no longer recruiting to completed.
- 10 Jan 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Oct 2023 New trial record